Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme

Executive Summary

Plans IND filings for two injectable products by the end of 1990: thyroid stimulating hormone (TSH) and Ananain. TSH is intended as an in vivo diagnostic as well as a therapeutic for thyroid cancer metastases. The drug would allow patients after thyroid removal to continue hormonal replacement therapy while undergoing full body radiation scan to treat metastases. The pineapple stem extract, Ananain, is being developed as a debriding agent to remove dead tissue from wounds such as skin ulcers and burns.

You may also be interested in...



Teva Takes On Amneal With Second US NuvaRing Rival

Teva has launched its generic version of NuvaRing in the US, adding a second rival generic to the market that already includes Amneal, as well as an authorized generic version from Prasco.

Stockwatch: Subdued Virtual J.P. Morgan Conference Prefaces Full-Year Earnings Season

Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.

Government Report Outlines Costs, Savings Of Major Regs

The US HHS was responsible for the most major regulations over the last few years of any agency, an OMB report shows.

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel